Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Colorectal Neoplasms 19Colonic Neoplasms 9Pancreatic Neoplasms 7Esophageal Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Follicular 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Bowel Adenocarcinoma 1Prostatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1

Interventions

Cyclophosphamide 11Biopsy 11Specimen Handling 10Rituximab 9Magnetic Resonance Spectroscopy 9obinutuzumab 6fludarabine 6Prednisone 6Lenalidomide 6pembrolizumab 5Nuclear Medicine Department, Hospital 5X-Rays 4Doxorubicin 4venetoclax 3fludarabine phosphate 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3GSK2636771 3Etoposide 3Busulfan 3Bendamustine Hydrochloride 3trametinib 2tocilizumab 2palbociclib 2osimertinib 2ipatasertib 2ibrutinib 2glofitamab 2erdafitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Oxaliplatin × 30 days × Clear all
NCT06624085 2026-06-03

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Phase 1 Recruiting
50 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡